Core Viewpoint - The Hong Kong stock market experienced significant net selling from northbound capital, totaling HKD 31.89 billion on September 16, with the majority coming from the Shanghai-Hong Kong Stock Connect [1] Group 1: Northbound Capital Flow - Northbound capital had a net selling of HKD 29.76 billion through the Shanghai Stock Connect and HKD 2.13 billion through the Shenzhen Stock Connect [1] - The stocks with the highest net buying included Alibaba-W (09988), Meituan-W (03690), and Baize Medical (02609) [1] - The stocks with the highest net selling included the Tracker Fund of Hong Kong (02800), Xiaomi Group-W (01810), and SMIC (00981) [1] Group 2: Individual Stock Performance - Alibaba-W (09988) saw a net inflow of HKD 30.31 billion, supported by recent announcements related to its mapping service and AI developments [4] - Meituan-W (03690) recorded a net inflow of HKD 7.15 billion, bolstered by the successful launch of its international delivery brand Keeta in Kuwait [5] - Baize Medical (02609) and Tongyuan Kang Medical-B (02410) received net inflows of HKD 3.27 billion and HKD 2.96 billion, respectively, following regulatory changes that enhance the clinical trial approval process for innovative drugs [5] Group 3: Notable Net Selling - The Tracker Fund of Hong Kong (02800) faced a significant net outflow of HKD 46.38 billion, with analysts suggesting that while short-term interest rates may benefit the Hong Kong market, the overall outlook remains cautious due to weakening fundamentals [7] - Xiaomi Group-W (01810), SMIC (00981), and Tencent (00700) experienced net outflows of HKD 5.69 billion, HKD 4.12 billion, and HKD 3.86 billion, respectively [8]

Group 1 - The Hang Seng Index rose by 0.07%, gaining 19 points to close at 26,465 points, while the Hang Seng Tech Index increased by 0.39% [1] - The early trading volume in Hong Kong stocks reached 160.2 billion HKD [1] Group 2 - New pharmaceutical stocks in the Hong Kong Stock Connect saw significant gains, with ZhiJie AnKang-B (02617) surging over 49%, reaching a market capitalization of over 240 billion HKD; BaiZe Medical (02609) rose over 76%; and TongYuanKang Pharmaceutical-B (02410) increased by over 36% [1] - Fosen Pharmaceutical (01652) experienced a dramatic rise of over 410%, closing at 1.35 HKD, up 297%, following the approval of Metformin and Ertugliflozin tablets [2] - Shanghai Fudan (01385) increased by 5.87%, with the company well-prepared for supply chain disruptions, and Morgan Stanley noted limited impact on demand [2] - SF Express (09699) rose over 6% as its "SoFast" service officially launched in Macau, with Daiwa optimistic about the company's revenue growth prospects [2] - Valiant Bio-B (09887) increased by over 13%, with its core product LBL-024 for melanoma completing its first patient dosing in trials [2] - Bilibili-W (09626) rose by 2.78%, accumulating a total increase of about 25% over the past six days, with the new game "Three Kingdoms: Hundred Generals" set for testing in October [2] - LionTeng Holdings (02562) surged over 7% as it plans to acquire leading companies in artificial intelligence and blockchain to expand its digital finance layout [2] - GCL-Poly Energy (03800) rose by 3.97%, planning a discounted placement to raise approximately 5.392 billion HKD for structural adjustments in polysilicon capacity [2] - China General Nuclear Power Corporation Mining (01164) increased by 6.7%, as the U.S. seeks to expand its strategic uranium reserves, with institutions expecting a recovery in uranium prices [2] - Yunfeng Financial (00376) fell over 16% after announcing a discounted placement to raise about 1.15 billion HKD [2]

Market Overview - The Hang Seng Index rose by 0.07%, gaining 19 points to close at 26,465 points, while the Hang Seng Tech Index increased by 0.39% [1] - Early trading volume in Hong Kong stocks reached HKD 160.2 billion [1] Notable Stock Movements - New pharmaceutical stocks in the Hong Kong Stock Connect surged, with Yaojie Ankang-B (02617) rising over 49%, reaching a market capitalization of over HKD 240 billion [1] - Baize Medical (02609) saw an increase of over 76% [1] - Tongyuan Kang Pharmaceutical-B (02410) rose by over 36% [1] Specific Company Highlights - Fosen Pharmaceutical (01652) experienced a dramatic rise of over 410%, closing at HKD 1.35, up 297%, following the approval of Metformin and Ertugliflozin tablets [2] - Shanghai Fudan (01385) increased by 5.87%, with the company prepared for supply chain disruptions, and Morgan Stanley noted limited impact on demand [2] - SF Express (09699) rose by over 6% as its "SoFast" service launched in Macau, with positive revenue growth prospects according to Daiwa [2] - Valiant Pharmaceuticals-B (09887) increased by over 13%, completing the first medication trial for its core product LBL-024 for melanoma [2] - Bilibili-W (09626) rose by 2.78%, accumulating a 25% increase over six days, with the new game "Three Kingdoms: Hundred Generals" set for testing in October [2] - Liontech Holdings (02562) surged over 7% as it plans to acquire a leading AI and blockchain company to expand its digital finance footprint [2] - GCL-Poly Energy (03800) rose by 3.97%, planning a discounted share placement to raise approximately HKD 5.392 billion for structural adjustments in polysilicon capacity [2] - CGN Mining (01164) increased by 6.7% amid expectations of rising uranium prices as the U.S. seeks to expand its strategic uranium reserves [2] - Yunfeng Financial (00376) fell over 16% after announcing a discounted share placement to raise about HKD 1.15 billion [2]

Group 1 - The core viewpoint of the article highlights the significant stock price surge of Baize Medical (2609.HK), which rose over 50% in one day and further increased by 94% to reach HKD 19.88, marking a total increase of 192% over two days, with a market capitalization exceeding HKD 26 billion [1] - Baize Medical is primarily engaged in investment and provision of medical services related to oncology, operating six proprietary for-profit hospitals and managing two non-profit hospitals across various regions including Beijing, Tianjin, and Anhui [1] - The company’s flagship hospital is Beijing Xiyuan Cancer Hospital, which offers core services such as cancer screening, diagnosis, treatment, and rehabilitation [1] Group 2 - The inclusion of Baize Medical in the Hong Kong Stock Connect program, effective from September 8, has contributed to its stock price surge [1]

Core Viewpoint - Baize Medical (02609) has seen a significant stock price increase of over 50%, reaching a new high of 17.06 HKD, with a cumulative rise of 130% over the past two trading days [1] Company Summary - As of the latest report, Baize Medical's stock price increased by 58.01%, trading at 16.19 HKD, with a trading volume of 1.437 billion HKD and a total market capitalization exceeding 20 billion HKD [1] - The company has been included in the Hong Kong Stock Connect list, effective from September 8, which has contributed to the increased trading activity [1] - Baize Medical operates in the "full-cycle cancer medical services" sector, providing services such as screening, diagnosis, treatment, and rehabilitation [1] - The company has successfully operated eight hospitals across five provinces and cities, including Beijing, Tianjin, Anhui, Shanxi, and Henan [1] - In the first half of the year, Baize Medical reported revenue of 575 million RMB, a year-on-year increase of 0.66%, while the loss attributable to shareholders widened to 27.62 million RMB, an increase of 139.18% year-on-year [1]

消息面上，上交所、深交所近日发布公告，佰泽医疗被调入港股通标的名单，自9月8日起生效。最新数 据显示，佰泽医疗港股通持股占比达0.21%。公开资料显示，佰泽医疗为"肿瘤全周期医疗服务"领域的 服务供应商，在肿瘤全周期医疗服务体系中提供筛查、诊断、治疗、康复等服务。在战略布局方面，佰 泽医疗已在北京、天津、安徽、山西、河南五省市成功运营八家医院。今年上半年，佰泽医疗实现收入 5.75亿元(人民币，下同)，同比增加0.66%；股东应占亏损2762万元，同比扩大139.18%。 智通财经APP获悉，佰泽医疗(02609)再暴涨超50%，高见17.06港元创上市新高，近两个交易日股价累 涨1.3倍。截至发稿，涨58.01%，报16.19港元，成交额14.37亿港元，总市值突破200亿港元。 ...

深港通（南向）十大活跃成交公司 | 公司名称 | 成交金额 | 净买入额 | | --- | --- | --- | | 阿里巴巴-W(09988) | 50.47 亿元 | +23.95 亿元 | | 小米集团-W(01810) | 25.76 亿元 | +457.14 万元 | | 腾讯控股(00700) | 18.75 亿元 | +2627.60 万元 | | 泡泡玛特(09992) | 18.72 亿元 | -1.27 亿元 | | 美团-W(03690) | 15.29 亿元 | +3.88 亿元 | | 药捷安康-B(02617) | 13.58 亿元 | +2.81 亿元 | | 中芯国际(00981) | 13.27 亿元 | -7742.31 万元 | | 盈富基金(02800) | 12.77 亿元 | +12.69 亿元 | | 康方生物(09926) | 12.05 亿元 | -2.29 亿元 | | 华虹半导体(01347) | 9.06 亿元 | +3.30 亿元 | 沪港通（南向）十大活跃成交公司 | 公司名称 | 成交金额 | 净买入额 | | --- | --- | --- ...

致：香港交易及結算所有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 公司名稱: 佰澤醫療集團 （根據開曼群島法律註冊成立的有限公司） 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02609 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | 0.00001 | USD | | 50,000 | 本月底法定/註冊股本 ...

Core Viewpoint - The Hong Kong IPO market is active, with 57 new listings and a total fundraising amount of 131.9 billion HKD as of August 25. However, many companies face challenges in meeting both domestic and Hong Kong regulatory requirements for listing [1]. Group 1: Hong Kong IPO Overview - As of August 25, 2023, there have been 57 new IPOs on the Hong Kong Stock Exchange, raising a total of 131.9 billion HKD [1]. - There are currently 211 companies that have submitted applications for listing in Hong Kong [1]. Group 2: Listing Challenges - Companies looking to list in Hong Kong must comply with both domestic laws and Hong Kong's regulatory framework, making the IPO preparation process complex and demanding [1]. Group 3: Resources for Companies - A compilation of Hong Kong listing rules and disclosure documents for domestic companies planning to list in Hong Kong has been organized to assist businesses in understanding the latest regulatory dynamics [1].

近日，佰泽医疗集团(股票代码：02609.HK)(下称 "佰泽医疗")正式发布 2025 年中期业绩公告。数据显 示，截至 2025 年 6 月 30 日，公司上半年实现收入约人民币 5.75 亿元，较 2024 年同期稳健增长 0.7%；毛利约人民币 1.06 亿元，同比提升 8.3%；经调整净利润(扣除上市费用)约人民币 940 万元，同 比大幅增长 72.8% 。在医疗行业市场环境复杂多变的背景下，佰泽医疗凭借清晰的战略布局与高效的 运营能力，展现出强劲的内生增长韧性与持续发展潜力。 ...